Clinical Trials Logo

Beckwith-Wiedemann Syndrome clinical trials

View clinical trials related to Beckwith-Wiedemann Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01842659 Active, not recruiting - Clinical trials for Pregnant Women Requiring Amniocentesis

Prenatal Screening for Imprinting Anomalies Implicated in Beckwith Wiedemann and Silver Russell Syndromes

DASIRUWIBE
Start date: May 2013
Phase: N/A
Study type: Interventional

Losses of imprinting are involved in various syndromes. Those occurring in the 11p15 region lead to Beckwith-Wiedemann and Silver-Russell Syndromes. These losses of imprinting follow a mosaic pattern, rendering their detection difficult, especially given the scarcity of available DNA in amniotic fluid. Thus, in spite of growing demand, prenatal diagnosis (PND) for imprinting abnormalities of the 11p15 region is not available. The recent development of a quantitative PCR method that permits the methylation index (MI) of imprinted regions to be calculated renders PND technically possible. Nevertheless, because of the mosaic nature of these anomalies, it is essential to verify that the methylation pattern of the 11p15 region obtained from the amniotic fluid matches that obtained from the blood.

NCT ID: NCT00945009 Active, not recruiting - Clinical trials for Rhabdoid Tumor of the Kidney

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Start date: July 13, 2009
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well combination chemotherapy and surgery work in treating young patients with Wilms tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery.